RATIONALE: Phosphorylation of sarcomeric proteins has been implicated in heart failure with preserved ejection fraction (HFpEF); such changes may contribute to diastolic dysfunction by altering contractility, cardiac stiffness, Ca2+-sensitivity, and mechanosensing. Treatment with cardiosphere-derived cells (CDCs) restores normal diastolic function, attenuates fibrosis and inflammation, and improves survival in a rat HFpEF model. OBJECTIVE: Phosphorylation changes that underlie HFpEF and those reversed by CDC therapy, with a focus on the sarcomeric subproteome were analyzed. METHODS AND RESULTS: Dahl salt-sensitive rats fed a high-salt diet, with echocardiographically verified diastolic dysfunction, were randomly assigned to either intracoronary CDCs or placebo. Dahl salt-sensitive rats receiving low salt diet served as controls. Protein and phosphorylated Ser, Thr, and Tyr residues from left ventricular tissue were quantified by mass spectrometry. HFpEF hearts exhibited extensive hyperphosphorylation with 98% of the 529 significantly changed phospho-sites increased compared with control. Of those, 39% were located within the sarcomeric subproteome, with a large group of proteins located or associated with the Z-disk. CDC treatment partially reverted the hyperphosphorylation, with 85% of the significantly altered 76 residues hypophosphorylated. Bioinformatic upstream analysis of the differentially phosphorylated protein residues revealed PKC as the dominant putative regulatory kinase. PKC isoform analysis indicated increases in PKC α, β, and δ concentration, whereas CDC treatment led to a reversion of PKCβ. Use of PKC isoform specific inhibition and overexpression of various PKC isoforms strongly suggests that PKCβ is the dominant kinase involved in hyperphosphorylation in HFpEF and is altered with CDC treatment. CONCLUSIONS: Increased protein phosphorylation at the Z-disk is associated with diastolic dysfunction, with PKC isoforms driving most quantified phosphorylation changes. Because CDCs reverse the key abnormalities in HFpEF and selectively reverse PKCβ upregulation, PKCβ merits being classified as a potential therapeutic target in HFpEF, a disease notoriously refractory to medical intervention.
RATIONALE: Phosphorylation of sarcomeric proteins has been implicated in heart failure with preserved ejection fraction (HFpEF); such changes may contribute to diastolic dysfunction by altering contractility, cardiac stiffness, Ca2+-sensitivity, and mechanosensing. Treatment with cardiosphere-derived cells (CDCs) restores normal diastolic function, attenuates fibrosis and inflammation, and improves survival in a rat HFpEF model. OBJECTIVE: Phosphorylation changes that underlie HFpEF and those reversed by CDC therapy, with a focus on the sarcomeric subproteome were analyzed. METHODS AND RESULTS: Dahl salt-sensitive rats fed a high-salt diet, with echocardiographically verified diastolic dysfunction, were randomly assigned to either intracoronary CDCs or placebo. Dahl salt-sensitive rats receiving low salt diet served as controls. Protein and phosphorylated Ser, Thr, and Tyr residues from left ventricular tissue were quantified by mass spectrometry. HFpEF hearts exhibited extensive hyperphosphorylation with 98% of the 529 significantly changed phospho-sites increased compared with control. Of those, 39% were located within the sarcomeric subproteome, with a large group of proteins located or associated with the Z-disk. CDC treatment partially reverted the hyperphosphorylation, with 85% of the significantly altered 76 residues hypophosphorylated. Bioinformatic upstream analysis of the differentially phosphorylated protein residues revealed PKC as the dominant putative regulatory kinase. PKC isoform analysis indicated increases in PKC α, β, and δ concentration, whereas CDC treatment led to a reversion of PKCβ. Use of PKC isoform specific inhibition and overexpression of various PKC isoforms strongly suggests that PKCβ is the dominant kinase involved in hyperphosphorylation in HFpEF and is altered with CDC treatment. CONCLUSIONS: Increased protein phosphorylation at the Z-disk is associated with diastolic dysfunction, with PKC isoforms driving most quantified phosphorylation changes. Because CDCs reverse the key abnormalities in HFpEF and selectively reverse PKCβ upregulation, PKCβ merits being classified as a potential therapeutic target in HFpEF, a disease notoriously refractory to medical intervention.
Entities:
Keywords:
echocardiography; fibrosis; heart failure; mass spectrometry; phosphorylation
Authors: H Sorimachi; A Freiburg; B Kolmerer; S Ishiura; G Stier; C C Gregorio; D Labeit; W A Linke; K Suzuki; S Labeit Journal: J Mol Biol Date: 1997-08-01 Impact factor: 5.469
Authors: Nazha Hamdani; Judith Krysiak; Michael M Kreusser; Stefan Neef; Cristobal G Dos Remedios; Lars S Maier; Markus Krüger; Johannes Backs; Wolfgang A Linke Journal: Circ Res Date: 2013-01-02 Impact factor: 17.367
Authors: Nazha Hamdani; Kalkidan G Bishu; Marion von Frieling-Salewsky; Margaret M Redfield; Wolfgang A Linke Journal: Cardiovasc Res Date: 2012-12-04 Impact factor: 10.787
Authors: Carlos Hidalgo; Bryan Hudson; Julius Bogomolovas; Yi Zhu; Brian Anderson; Marion Greaser; Siegfried Labeit; Henk Granzier Journal: Circ Res Date: 2009-08-13 Impact factor: 17.367
Authors: Ralph Knöll; Masahiko Hoshijima; Hal M Hoffman; Veronika Person; Ilka Lorenzen-Schmidt; Marie-Louise Bang; Takeharu Hayashi; Nobuyuki Shiga; Hideo Yasukawa; Wolfgang Schaper; William McKenna; Mitsuhiro Yokoyama; Nicholas J Schork; Jeffrey H Omens; Andrew D McCulloch; Akinori Kimura; Carol C Gregorio; Wolfgang Poller; Jutta Schaper; Heinz P Schultheiss; Kenneth R Chien Journal: Cell Date: 2002-12-27 Impact factor: 41.582
Authors: Ling Gao; Zachery R Gregorich; Wuqiang Zhu; Saidulu Mattapally; Yasin Oduk; Xi Lou; Ramaswamy Kannappan; Anton V Borovjagin; Gregory P Walcott; Andrew E Pollard; Vladimir G Fast; Xinyang Hu; Steven G Lloyd; Ying Ge; Jianyi Zhang Journal: Circulation Date: 2017-12-12 Impact factor: 29.690
Authors: Mahdi Hesaraki; Ugur Bora; Sara Pahlavan; Najmeh Salehi; Seyed Ahmad Mousavi; Maryam Barekat; Seyed Javad Rasouli; Hossein Baharvand; Gunes Ozhan; Mehdi Totonchi Journal: Front Cardiovasc Med Date: 2022-04-08
Authors: María Valero-Muñoz; Eng Leng Saw; Ryan M Hekman; Benjamin C Blum; Zaynab Hourani; Henk Granzier; Andrew Emili; Flora Sam Journal: Front Cardiovasc Med Date: 2022-08-25
Authors: Marco Guazzi; Matthias Wilhelm; Martin Halle; Emeline Van Craenenbroeck; Hareld Kemps; Rudolph A de Boer; Andrew J S Coats; Lars Lund; Donna Mancini; Barry Borlaug; Gerasimos Filippatos; Burkert Pieske Journal: Eur J Heart Fail Date: 2022-07-31 Impact factor: 17.349